Moon­Lake's PhII da­ta on skin dis­ease set it up against Cosen­tyx, UCB and oth­ers in IL-17 field

Moon­Lake Im­munother­a­peu­tics says it’s cleared the bar in a Phase II tri­al of its IL-17A and IL-17F in­hibitor in hidradeni­tis sup­pu­ra­ti­va.

In its 234-pa­tient MI­RA study, Moon­Lake said it suc­ceed­ed on the pri­ma­ry goal — more pa­tients on its in­ves­ti­ga­tion­al med sonelokimab achieved at least a 75% re­duc­tion from base­line in to­tal ab­scess and in­flam­ma­to­ry nod­ule count than those on place­bo. Peo­ple with HS ex­pe­ri­ence re­cur­ring nod­ules and ab­scess­es in the armpits, groin and but­tocks, and si­nus tracts. It leads to pain and some­times stigma­ti­za­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER